BIN-67高钙血症型卵巢小细胞癌（SCCOHT）NTCC™ovarian small cell carcinoma cell line BioVector保藏中心

价　　格：¥99850
货　　号：NTCC™BIN-67
产　　地：北京

竭诚为您服务！

BioVector NTCC典型培养物保藏中心: 联系人：Dr.Xu, Biovector NTCC Inc.; 电话：400-800-2947 工作QQ:1843439339 (微信同号); 邮件：Biovector@163.com; 手机：18901268599; 地址：北京; 已注册

详细信息
咨询记录(共0条)

The NTCC™BIN-67 cell line is a human cancer cell line derived from a metastatic pelvic nodule of a patient with ovarian small cell carcinoma of the hypercalcemic type (SCCOHT). It is a rare and highly aggressive form of ovarian cancer that typically affects young women. BIN-67 is one of the few available cell lines for this specific type of cancer, making it an invaluable tool for research.

Catalogue of copy number variations and LOH in BIN-67 cell line | Download Table

Establishment and characterization of a novel cell line (SCCOHT-CH-1) and PDX models derived from Chinese patients of small cell ovarian carcinoma of the hypercalcemic type | Human Cell

Key Characteristics

Origin: The cell line was established in 1986 from a metastatic lesion, not the primary tumor itself.
Genetic Profile: Unlike many other ovarian cancers, the BIN-67 cell line exhibits a relatively stable genome with few chromosomal anomalies. It lacks common mutations in genes like TP53, KRAS, and BRAF. A key genetic feature is a loss-of-function mutation in the SMARCA4 gene, which is a highly specific and sensitive marker for SCCOHT.
Biochemical Properties: A defining characteristic of the BIN-67 cell line is its high expression of calcitonin receptors (CTR). It responds to calcitonin stimulation with a significant increase in cyclic AMP (cAMP), a key signaling molecule. This response is linked to the hypercalcemia (high calcium levels) often seen in patients with this type of cancer.
Therapeutic Response: BIN-67 cells are known to be resistant to many standard chemotherapeutic drugs, such as platinum-based agents. However, they have shown a sensitivity to oncolytic viruses in some studies, suggesting a potential alternative treatment pathway.

Research Applications

The BIN-67 cell line is a critical resource for studying SCCOHT, a cancer that is poorly understood due to its rarity. Researchers use this cell line to:

Model SCCOHT: It serves as a representative model for the disease, allowing scientists to investigate its unique biological and genetic characteristics.
Investigate Cancer Biology: The cell line is used to study the function of the SMARCA4 gene and the role of the SWI/SNF chromatin remodeling complex in tumor formation.
Drug Development: It is a valuable tool for screening and testing new therapeutic agents and strategies, especially for a cancer that is largely resistant to conventional treatments.

BIN-67 细胞系是一种人类癌细胞系，源自一名患有**高钙血症型卵巢小细胞癌（SCCOHT）**患者的盆腔转移性结节。SCCOHT 是一种罕见且高度侵袭性的卵巢癌，通常影响年轻女性。BIN-67 是目前针对这种特殊癌症类型为数不多的可用细胞系之一，使其成为研究的宝贵工具。

主要特点

来源: 该细胞系于1986年从一个转移性病灶而非原发肿瘤中建立。
遗传学特征: 与许多其他卵巢癌不同，BIN-67 细胞系具有相对稳定的基因组，染色体异常较少。它缺乏 TP53、KRAS 和 BRAF 等基因中常见的突变。其一个关键遗传特征是 SMARCA4 基因的功能缺失性突变，这是 SCCOHT 的高度特异性及敏感性标志物。
生化特性: BIN-67 细胞系的一个决定性特征是其降钙素受体 (CTR) 的高表达。它对降钙素刺激反应强烈，会显著增加关键信号分子——环磷酸腺苷 (cAMP) 的水平。这种反应与该类型癌症患者常见的高钙血症（高钙水平）相关。
治疗反应: 已知 BIN-67 细胞对许多标准化疗药物（如铂类药物）具有耐药性。然而，一些研究表明它们对溶瘤病毒敏感，这提示了一种潜在的替代治疗途径。